喘可治注射液辅助治疗小儿咳喘性疾病的临床观察

Clinical Observation of Chuankezhi Injection in the Adjuvant Therapy of Respiratory Tract Infection-induced Cough and Asthma

目的:观察喘可治注射液辅助治疗小咳喘性疾病的临床疗效与安全性。方法:选择2017年1月至2017年12月期间在我科住院的61例有咳喘症候群的下呼吸道感染性疾病的患儿,随机分为治疗组30例和对照组31例,对照组进行常规的抗炎、雾化吸入及对症、支持等治疗;治疗组在常规治疗的基础上加用喘可治注射液雾化吸入。比较两组主要症状、体征的改善情况及住院时间。结果:治疗组总有效率为90.0%,对照组总有效率为58.1%,治疗组疗效明显优于对照组(P<0.05)。治疗前两组患儿血气指标无明显差异,P>0.05,治疗结束后研究组各项血气指标优于对照组,研究组症状消失时间及住院时间上短于对照组,差异显著,P<0.05。结论:有咳喘症候群的下呼吸道感染性疾病的患儿在常规治疗的基础上加用喘可治雾化吸入治疗,能显著改善咳喘症候群患儿的临床主要症状、体征,缩短住院时间,疗效明显,值得临床推广应用。

Objective: To observe the clinical efficacy and safety of Chuankezhi injection in the adjuvant therapy of respiratory tract infection-induced cough and asthma. Methods: 61 lower respiratory tract infection children with cough and asthma(2017.01-2017.12) were selected and randomly assigned to treatment group(n=30)and control group(n=31). The control group was treated with conventional anti-inflammation, aerosol inhalation, symptomatic treatment and support, etc. On the basis of the former, the treatment group took the aerosol inhalation of Chuankezhi injection. The major symptom and vital sign improvement conditions and hospitalization time were compared. Results: The total effective rate in the treatment group(90.0%)was higher than control group(58.1%)(P<0.05);before treatment, blood gas indicators between groups were not significantly different(P>0.05);after treatment, blood gas indicators in the treatment group were better than control group;symptom relief time and hospitalization time was shorter than control group(P<0.05). Conclusion: The conventional treatment and Chuankezhi injection can remarkably improve children’s major symptoms and vital signs, shorten the hospitalization time and increase the clinical efficacy, It is worthy of clinical promotion and application.